Drug Approval | January 10, 2023
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Chyawanprash Special will be available at all Jan Aushadhi Kendras
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Greenko ZeroC will supply Carbon Free Energy and enable Green Hydrogen along with its various chemical derivatives.
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Subscribe To Our Newsletter & Stay Updated
